Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. J Exp Clin Cancer Res. 2020 Nov 09; 39(1):236.